Acta Pharmaceutica 2009-09-01

Development and optimization of a sublingual tablet formulation for physostigmine salicylate.

Noushin Bolourchian, Naghmeh Hadidi, Seyed Mohsen Foroutan, Bijan Shafaghi

Index: Acta. Pharm. 59(3) , 301-12, (2009)

Full Text: HTML

Abstract

This study is aimed to design and optimize a sublingual tablet formulation of physostigmine salicylate, an effective drug in Alzheimer's disease and nerve gas poisoning, by means of the D-optimal experimental design methodology. Polyvinyl pyrrolidone, lactose, starch 1500 and sodium starch glycolate were used in the formulations as independent variables. Tablets were prepared by the direct compression method and evaluated for their physical properties (tablet hardness, disintegration time and friability), which were regarded as responses in a D-optimal design. Due to the significance of the special cubic model for data fitted, compared to other models, it was used to examine the obtained results. Response surface plots were plotted to study the tablet properties and the optimized overlay plot was generated based on the results and targets considered for the responses. After verification of the optimum checkpoint formulations, an optimized formulation was chosen due to its desirable physical properties and closely observed and predicted values. Drug assay, content uniformity of the dosage unit, drug dissolution and accelerated stability studies were done on the optimum formulation as further experiments. All the obtained results complied with the requirements of a sublingual tablet formulation.


Related Compounds

Related Articles:

Possible interaction of cholinergic and GABAergic systems between MS and CA1 upon memory acquisition in rats.

2012-12-01

[Behav. Brain Res. 235(2) , 231-43, (2012)]

The effects of physostigmine infusion on patients with panic disorder.

1991-04-01

[Biol. Psychiatry 29(7) , 658-64, (1991)]

Liquid chromatographic analysis of physostigmine salicylate and its degradation products.

1999-01-01

[J. Pharm. Biomed. Anal. 18(6) , 939-45, (1999)]

Brain neurotransmitter systems mediating behavioral deficits produced by inescapable shock treatment in rats.

1988-04-26

[Brain Res. 447(1) , 122-32, (1988)]

Toxicity study of continuous administration of physostigmine salicylate.

1988-11-01

[Pharmacol. Biochem. Behav. 31(3) , 627-31, (1988)]

More Articles...